Get the Stockscreener App
58.31
0.71%
-0.395
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $58.31, with a volume of 4.80M.
It is down -0.71% in the last 24 hours and down -0.42% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$58.71
Open:
$58.21
24h Volume:
4.80M
Relative Volume:
0.39
Market Cap:
$119.03B
Revenue:
$48.19B
Net Income/Loss:
$7.06B
P/E Ratio:
16.86
EPS:
3.4587
Net Cash Flow:
$12.85B
1W Performance:
-1.42%
1M Performance:
-0.42%
6M Performance:
+34.35%
1Y Performance:
+21.70%
1-Day Range:
$58.10
$59.12
1-Week Range:
$57.79
$59.73
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.30 | 119.87B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
880.51 | 789.69B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
225.58 | 547.64B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
198.57 | 351.47B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
188.00 | 294.27B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
144.89 | 277.58B | 54.72B | 14.02B | 15.32B | 7.1855 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
3 Biotech Stocks That Could Benefit from the Patent Cliff - Investing.com
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS - Yahoo Finance UK
Is Bristol Myers Squibb the Best Bargain in Big Pharma? - Yahoo Finance
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield - Yahoo Finance
Bristol-Myers Squibb stock (US1078421011): Why Google Discover changes matter more now - AD HOC NEWS
Why Investors Hold Medtronic, Sanofi, and Bristol Myers Squibb for DividendsNews and Statistics - IndexBox
Bristol-Myers Squibb Precision Oncology Deal Meets Mixed Valuation Signals - Yahoo Finance
PUTNAM GLOBAL HEALTH CARE FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) and Pfizer (PFE) Launch Eliquis on Co - GuruFocus
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Bristol Myers Squibb-Pfizer Alliance to sell Eliquis on Mark Cuban’s Cost Plus Drugs - ROI-NJ
Bristol Myers Squibb Becomes Stable Choice for Defensive Portfolios - HarianBasis.co
Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios - insidermonkey.com
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy - Reuters
Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company - Yahoo Finance
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb: Strong Pipeline, Weak Outlook (Rating Downgrade) - Seeking Alpha
Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com Australia
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
Multi-Manager Large Cap Growth Strategies Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
MFS Global Alternative Strategy Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb donates lab equipment to Seton Hall - NJBIZ
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Milestone Asset Management LLC Invests $2.25 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com
Atrium lands $15M after delivering first heart drug candidate - Stock Titan
BMY Stock Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb files WARN notice for 206 jobs - ROI-NJ
Pharmaceutical Giant Laying Off Hundreds More In NJ - Patch
61,789 Shares in Bristol Myers Squibb Company $BMY Bought by CPC Advisors LLC - MarketBeat
Bristol-Myers Squibb Company stock (US0897961004): Why does its oncology dominance matter more now f - AD HOC NEWS
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? - Yahoo Finance
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
BMY Expands Partnership with Foundation Medicine for Diagnostic Development - GuruFocus
New cancer test aims to find patients with hard-to-detect MTAP deletion - Stock Titan
Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - GlobeNewswire Inc.
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - GlobeNewswire Inc.
Bristol-Myers Squibb stock (US1078421011): Is its oncology dominance strong enough to unlock new ups - AD HOC NEWS
Lobbying Update: $1,320,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
AQR Equity Market Neutral Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1? - TradingView
Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
The top 20 pharma companies by 2025 revenue - Fierce Pharma
Bristol Myers Squibb Stock Forecast: What’s Driving Focus - Kalkine Media
Assetmark Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to cut 206 more jobs in New Jersey (updated) - NJBIZ
Bristol-Myers Squibb Company Solicits Proxies from Shareholders - marketscreener.com
Virtus Silvant Large-Cap Growth Stock Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Why Bristol Myers Squibb (BMY) outpaced the stock market today - MSN
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):